IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results